Navigation Links
FDA approves Vidaza label expansion
Date:8/21/2008

Washington D.C. (August 21, 2008) The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is pleased to inform patients that the U.S. Food & Drug Administration (FDA) has expanded the label for VIDAZA (azacitidine) to include data from the AZA-001 trial, which found that Vidaza is the only agent that extends survival in MDS (myelodysplastic syndromes) patients. Vidaza was also shown to delay progression to acute myelogenous leukemia (AML) in patients with MDS. Roughly 30 percent of patients diagnosed with MDS will progress to AML.

"We are very encouraged by the Vidaza data from the AZA-001 trial. This trial showed, for the first time, a drug can extend survival for MDS patients," said John Huber, Executive Director of the Aplastic Anemia and MDS International Foundation. "We are excited to see that in this trial Vidaza also reduced the need for blood transfusions."

MDS occur when the bone marrow stem cells malfunction. This results in the production of too many defective blood cells and not enough normal cells. Diagnosis is made through blood tests and a bone marrow biopsy. Once diagnosed, treatment and evaluation should occur under the care of a hematologist or hematologist/oncologist. There are many subtypes of MDS classified according to how the disease manifests itself in the blood and marrow of the patient. Treatments include blood transfusions, growth factors, chemotherapy and bone marrow transplant.


'/>"/>

Contact: Chelsey Flaherty
cflaherty@webershandwick.com
212-445-8274
Weber Shandwick Worldwide
Source:Eurekalert

Page: 1

Related biology news :

1. Court Approves Scheme of Arrangement
2. Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarcs ID Systems Business
3. American College of Medical Genetics responds to new FDA labeling decision for warfarin
4. Got calcium? UWM researcher finds that food labels confuse consumers
5. Doctors may be giving the wrong dosage of adrenaline in an emergency because of labelling
6. LaserCard Corporation Announces Expansion of Middle East Project
7. Smithsonian identifies invasive crab species in Panama Canal expansion area
8. Smithsonian identifies invasive crab species in Panama Canal expansion area
9. SCI marks expansion into Asia with the launch of SCI INDIA
10. Experimental Biology and Medicine announces expansion into Asia, opens new office
11. AAAE Applauds Expansion of Registered Traveler Program to Nations Capital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017 ... by 2021, ABI Research identifies four technologies that ... solutions to secure significant share in the changing ... payments, and passive authentication.   "Companies ... it comes to security," says Dimitrios Pavlakis ...
(Date:2/13/2017)... Feb. 13, 2017  RSA Conference -- RSA, a ... is designed to enhance fraud detection and investigation ... the RSA Fraud & Risk Intelligence Suite. The ... leverage additional insights from internal and external sources ... protect their customers from targeted cybercrime attacks. ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers face a fundamental ... samples to full-size tissues, bones, even whole organs to implant in people to ... blood deep into the developing tissue. , Current bioengineering techniques, including 3-D ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
Breaking Biology Technology: